Targeting ferritinophagy via NCOA4-FTH1 disruption by sodium tanshinone IIA sulfonate alleviates cardiotoxicity and enhances anti-tumor efficacy.
BACKGROUND Sorafenib remains a first-line therapy for advanced hepatocellular carcinoma (HCC), yet its clinical utility is frequently limited by dose-dependent cardiotoxicity for which no targeted intervention exists. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has been imp...